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ABSTRACT
OBJECTIVES This study sought to examine the relationship between access site practice and clinical outcomes in
patients requiring percutaneous coronary intervention (PCI) following thrombolysis for ST-segment elevation myocardial
infarction (STEMI).
BACKGROUND Transradial access (TRA) is associated with better outcomes in patients requiring PCI for STEMI.
A signiﬁcant proportion of STEMI patients may receive thrombolysis before undergoing PCI in many countries across
the world. There are limited data around access site practice and its associated outcomes in this cohort of patients.
METHODS The author used the British Cardiovascular Intervention Society dataset to investigate the outcomes of
patients undergoing PCI following thrombolysis between 2007 and 2014. Patients were divided into TRA and
transfemoral access groups depending on the access site used. Multiple logistic regression and propensity score
matching were used to study the association of access site with in-hospital and long-term mortality, major bleeding,
and access site–related complications.
RESULTS A total of 10,209 patients received thrombolysis and PCI during the study time. TRA was used in 48%
(n ¼ 4,959) of patients; 3.3% (n ¼ 336) patients died in hospital, 1.6% (n ¼ 165) of patients experienced major bleeding,
4.2% (n¼ 437) experiencedmajor adverse cardiac events (MACE), and 4.6% (n¼ 468) experienced 30-daymortality. After
multivariate adjustment, TRAwas associatedwith signiﬁcantly reduced odds of in-hospital mortality (odds ratio [OR]: 0.59;
95% conﬁdence interval [CI]: 0.42 to 0.83; p¼0.002), major bleeding (OR: 0.45; 95% CI: 0.31 to 0.66; p<0.001), MACE
(OR: 0.72; 95% CI: 0.55 to 0.94; p ¼ 0.01), and 30-day mortality (OR: 0.72; 95% CI: 0.55 to 0.94; p ¼ 0.01).
CONCLUSIONS TRA is associated with decreased odds of bleeding complications, mortality, and MACE in patients
undergoing PCI following thrombolysis and should be preferred access site choice in this cohort of patients.
(J Am Coll Cardiol Intv 2017;10:2258–65) © 2017 by the American College of Cardiology Foundation.
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P
rimary percutaneous coronary intervention
(PPCI) is currently the gold standard treat-
ment for patients with ST-segment elevation
myocardial infraction (STEMI) (1,2). However, throm-
bolysis is still widely used particularly in areas where
PPCI services are not well established or cannot be
delivered within recommended time frames.
Although use of thrombolytic treatment has declined
over recent years, it still remains an important reper-
fusion strategy for the management of patients
admitted with STEMI across Europe (3), the United
States (4,5), and the Far East (6). For instance, one
of the largest analyses of STEMI care in China re-
ported approximately 27% of the patients received
thrombolysis as main reperfusion therapy (6) and a
similar percentage (29.5%) has been reported from
registry data in the United States (7). A signiﬁcant
proportion of these patients may require PCI either
due to failure of therapy or incomplete resolution of
symptoms (7). Use of potent antithrombotic and anti-
platelets in addition to ﬁbrinolytic agents is likely to
increase the risk of bleeding complications in those
undergoing rescue PCI (8,9). For instance, in the
FINESSE (Facilitated Intervention with Enhanced
Reperfusion Speed to Stop Events) trial (10), Throm-
bolysis In Myocardial Infarction major and minor
bleeding rates were signiﬁcantly higher (14.5% and
10.1%, respectively) in patients receiving thrombo-
lytic agents compared with those undergoing PPCI
only (6.9%; p < 0.001). Major bleeding is one of the
most serious complications of PCI and is indepen-
dently associated with reduced survival and poor
outcomes (11).
Adoption of transradial access (TRA) has increased
signiﬁcantly over the past decade for acute coronary
interventions across the whole spectrum of acute
syndromes (12,13). This uptake is mainly driven by
the evidence that TRA is associated with signiﬁcant
reduction in access site related bleeding complica-
tions and improved survival in patients undergoing
PCI for acute coronary syndrome as well as PPCI
(14–17). Importantly, there is little evidence around
outcomes and the access site used in patients
requiring PCI after receiving thrombolysis with ma-
jority of these data conﬁned to patients undergoing
PPCI (14,15). Previously, the impact of access site
practice in patients requiring PCI following
thrombolysis was only described in either
highly selected post hoc analyses of ran-
domized trials (18,19) or in observational
studies where use of TRA is signiﬁcantly
lower compared to transfemoral access (TFA)
(20,21). These studies reported inconsistent
results and were not statistically powered,
with TRA patients being <15% of the total
cohort. A study from the well-known CathPCI
registry showed that TRA is associated with
reduced major in-hospital and gastrointes-
tinal bleeding complications, but not mor-
tality (20), albeit only 14.2% of the cases
received TRA compared with TFA. Another
study encompassing individual patients level
data of 1,891 patients from 7 STEMI trials
evaluating PCI after thrombolysis reported no
difference in major bleeding and mortality at
30-days in TRA versus TFA although TRA was
only used in 17% of the patients (18). In
contrast, a recent post hoc analysis of the STREAM
(STrategic Reperfusion Early After Myocardial
Infarction) study, Shavadia et al. (19) illustrated that
TRA was associated with signiﬁcant reduction in
major bleeding and mortality at 30-days in patients
undergoing rescue PCI after thrombolysis.
In the current study, we sought to investigate trends
in procedure practice and impact of access site selec-
tion on cardiovascular outcomes in a national cohort of
patients undergoing PCI after receiving thrombolysis
treatment using British Cardiovascular Interventional
Society (BCIS) dataset in England and Wales.
METHODS
This study is a retrospective analysis of prospectively
collected national data for all patients undergoing PCI
after receiving thrombolysis for STEMI in England
and Wales from January 2007 to December 2014 in the
British Cardiovascular Intervention Society (BCIS)
database. BCIS records information on PCI practices
in the United Kingdom with data collection managed
by the National Institute of Cardiovascular Outcomes
Research (22–25). The BCIS database is one of the
largest nationally collected datasets containing 113
clinical, procedural, and outcome variables with
80,000 new records added each year. Using the
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patient’s unique National Health Service number,
mortality is tracked for all patients using data from
the Ofﬁce of National Statistics in England and Wales.
Patients from Scotland and Northern Ireland were
excluded from the mortality outcome analysis
because of the absence of the Ofﬁce of National Sta-
tistics–linked mortality data. All the data were
collected as part of a national audit and were ano-
nymized; therefore, institutional review board
approval was not required for this study.
VARIABLES AND OUTCOMES COLLECTED. We
collected data on participants’ demographic such as
age and sex, cardiovascular risk factors, comorbid-
ities, and indication for PCI. In addition, data were
also collected on clinical characteristics such left
ventricular ejection fraction, cardiogenic shock, use
of pharmacological or mechanical inotropic support,
and all aspects of the interventional treatment and
adjunctive pharmacology.
STUDY DEFINITIONS. Thrombolytic PCI (tPCI) in the
BCIS dataset is deﬁned as acute coronary syndrome
(ACS)–facilitated PCI for STEMI (lysisþPCI), ACS
rescue PCI for STEMI (failed lysis), and ACS rescue PCI
for reinfarction (failed lysis). Use of either radial artery
is classed as TRA and use of either femoral artery was
deﬁned as TFA, whereas multiple arterial access,
brachial access, and unlisted access site were excluded
from the analysis. We evaluated all-cause mortality in
hospital, at 30 days, and at 1 year of follow-up. We also
examined in-hospital major adverse cardiac events
(MACE) (deﬁned as a composite of in-hospital mor-
tality, in-hospital myocardial infarction, or reinfarc-
tion and revascularization [emergency PCI or coronary
artery bypass grafting]) and in-hospital major bleeding
(deﬁned as blood or platelet transfusion, intracerebral
hemorrhage, retroperitoneal hemorrhage, bleed
resulting in cardiac tamponade, or an arterial access
site bleeding requiring surgery or intervention).
Finally, we also studied the in-hospital mortality only
and access site complications (deﬁned as pseudo-
aneurysm or any access site hemorrhage requiring
intervention or delaying discharge).
STATISTICAL METHODS. After initial selection of
tPCI cohort as deﬁned previously, we divided the
study population into 2 groups: 1) tPCI undertaken via
TRA; and 2) tPCI performed via TFA. We made further
exclusions depending on missing information from
age, sex, or in-hospital mortality. The characteristics
of patients were compared across the 2 groups. These
comparisons were performed using analysis of vari-
ance for continuous variables and Fisher exact tests
for binary or categorical variables.
We used multiple imputation techniques with
chained equations to impute data for all variables
with missing information to account for the missing
data and protect against the biases because of infor-
mative missing data mechanisms. Age, sex, access,
indication for PCI, and study outcomes were regis-
tered as complete variables in the imputation models,
which were used to generate 10 datasets on which we
ran the analyses (imputed variables were body mass
index, history of previous PCI, history of coronary
artery bypass grafting, diabetes mellitus, smoking
status, hypertension, hyperlipidemia, previous
myocardial infarction, previous stroke, peripheral
vascular disease, history of renal failure, glycoprotein
IIb or IIIa use, cardiogenic shock, mechanical or
pharmacological circulatory support, use of stents,
mechanical ventilation, bivalirudin use, history of
triple-vessel disease, and PCI to left main stem ar-
tery). Although our use of a multiple imputation
framework rests on a missing at random assumption
and levels of missingness are high for certain vari-
ables, it has been shown that multiple imputation
frameworks are robust even when levels of
FIGURE 1 Flow Diagram of Study Selection
Study selection from BCIS registry. BCIS ¼ British Cardiovascular Intervention Society;
PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial
infarction.
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missingness are extremely high, although they can
offer some protection when data are missing not at
random (26).
The risk of adverse outcomes by access group was
estimated with multivariable logistic regression
adjusting for all patient and clinical characteristics.
All potential predictors of 30-day mortality were
included in the model. These were age, sex, and left
ventricular function in addition to all the variables
included in the multiple-imputation model.
To better control for any differences in the baseline
characteristics of the 2 groups (TRA vs. TFA), we used
multiple imputations with propensity score matching
(mi estimate:teffects psmatch) to estimate the average
treatment effect using the same covariates as in our
main multiple logistic regression analysis (Online
Table 1). The propensity scores of the radial and
femoral procedures were graphically plotted before
matching. After matching the scores are plotted for
the cases (radial) and control subjects (femoral) to
allow for graphically evaluation of the quality of
matching (Online Figure 1). We also conducted a
sensitivity analysis in the nonimputed dataset to
assess the consistency of results (Online Table 2). Due
to missing information the sample size drop signiﬁ-
cantly hence the conﬁdence intervals overlap; how-
ever, over trend it remains same as in the imputed
dataset. Statistical analyses were performed using
Stata version 13.1 (StataCorp, College Station, Texas).
RESULTS
BASELINE CHARACTERISTICS. A total of 11,526 pa-
tients received thrombolysis and PCI between 2007 to
2014 in England and Wales for STEMI. After making
exclusions based on missing information on access
site, age, sex, and in-hospital mortality as well as
patients with multiple access sites used, 10,209 pa-
tients were included in the ﬁnal analyses (Online
Table 3). Full information of study inclusion and
exclusion is shown in Figure 1. Among the 10,209
patients receiving thrombolysis for STEMI and tPCI,
5,250 (51%) received their procedure via TFA and
4,959 (48%) received their procedure via TRA. As
shown in Table 1, patients in the TFA group were
more likely to have hypertension, previous history of
acute myocardial infarction, hypercholesterolemia,
diabetes, history of previous coronary artery bypass
grafting, and triple-vessel disease (p < 0.01). They
were also signiﬁcantly more likely to have cardio-
genic shock requiring pharmacological or mechanical
inotropic support. The TRA group received more
aggressive and potent pharmacotherapy than the TFA
group did, in the form of prasugrel (2.6% vs. 0.5%),
ticagrelor (2.9% vs. 0.7%), and bivalirudin (2.8% vs.
1.3%) (p < 0.01).
PROCEDURE TRENDS. During the study time, the
number of patients requiring PCI after thrombolysis
reduced signiﬁcantly from 38% in 2007 to 1.2% in
2014, shown in Figure 2A. The use of TRA in patients
requiring PCI following thrombolysis versus PPCI is
illustrated in Figure 2B, showing a greater uptake of
TRA in patients requiring tPCI. There was a
TABLE 1 Baseline and Procedural Characteristics of Patients Undergoing Transradial or
Transfemoral Access Percutaneous Coronary Intervention Following Thrombolysis
Femoral
(n ¼ 5,250)
Radial
(n ¼ 4,959) p Value
Age, yrs 60.9  11.9 60.3  11.5 0.039
Male 4,079 (78.0) 4,061 (82.0) <0.001
BMI, kg/m2 27.6  4.6 28.4  4.9 <0.001
Hypercholesterolemia 1,950 (40.0) 1,933 (43.0) <0.001
HTN 1,835 (37.8) 1,819 (40.5) <0.008
Renal failure 35 (0.7) 22 (0.4) 0.11
Smoking 3,149 (71.3) 3,166 (69.6) 0.05
Diabetes 657 (13.3) 541 (11.2) <0.001
Previous AMI 872 (19.5) 629 (13.5) <0.001
Previous CVA 98 (2) 119 (2.6) 0.04
Severe LVSD 238 (13.5) 147 (6.8) <0.001
PVD 124 (2.5) 131 (2.9) 0.28
Previous PCI 370 (7.5) 292 (6.0) <0.001
Previous CABG 313 (8.5) 105 (3.1) <0.001
Pharmacological inotropes 204 (4.3) 46 (0.9) <0.001
IABP 388 (8.3) 93 (1.9) <0.001
Cardiogenic shock 513 (10.0) 190 (3.9) <0.001
Ventilated 259 (6.2) 93 (2.3) <0.001
GP IIb/IIIa use 2,295 (46.0) 2,107 (43.3) 0.003
Clopidogrel 3,450 (75.0) 3,281 (77.4) 0.007
Warfarin 22 (0.48) 19 (0.45) 0.83
Bivalirudin 58 (1.3) 120 (2.8) <0.001
Prasugrel 26 (0.5) 113 (2.6) <0.001
Ticagrelor 35 (0.7) 122 (2.9) <0.001
LMS PCI 106 (2.0) 59 (1.1) <0.001
Triple vessel disease 283 (15.0) 225 (10.0) <0.001
Stent use
No stent 264 (5.2) 247 (5.1)
BMS only 2,396 (47.9) 2,016 (41.7) <0.001
DES only 2,172 (43.4) 2,400 (49.6) <0.001
BMS and DES 169 (3.3) 169 (3.5)
Access site complications 136 (2.5) 33 (0.6) <0.001
In hospital death 247 (4.7) 89 (1.8) <0.001
MACE 302 (5.7) 135 (2.7) <0.001
Major bleeding 116 (2.2) 49 (1.0) <0.001
30-day mortality 349 (7.5) 119 (3.7) <0.001
1-yr mortality 458 (9.8) 181 (5.6) <0.001
Values are mean  SD or n (%). Major adverse cardiovascular event(s) (MACE) were deﬁned as composite of in-
hospital mortality, in-hospital myocardial infarction or reinfarction, and revascularization (emergency percuta-
neous coronary intervention [PCI] or coronary artery bypass grafting [CABG]).
AMI ¼ acute myocardial infarction; BMI ¼ body mass index; BMS ¼ bare-metal stent(s); CVA ¼ cerebrovascular
accident; DES ¼ drug-eluting stent; GP ¼ glycoprotein; HTN ¼ hypertension; IABP ¼ intra-aortic balloon pump;
LMS ¼ left main stem; LVDS ¼ left ventricular systolic dysfunction; PVD ¼ peripheral vascular disease.
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particularly steep rise in the use of TRA for tPCI
(almost doubling) from 43% in 2009 to 82% in 2012.
Online Figures 2A and 2B demonstrate a cognate
decline in number of patient undergoing PCI after the
administration of thrombolysis in all parts of the
United Kingdom corresponding with an overall in-
crease in uptake of TRA at national level. However,
we observed signiﬁcant regional variation within the
United Kingdom in use of PCI following thrombolysis.
For instance, in the primary care Trusts encompass-
ing North Wales, 53% of STEMI PCI patients had
received thrombolysis in 2014. Conversely, in the
mainland areas such as North West and Midlands of
England the use of tPCI has declined signiﬁcantly,
to <10%. Similarly, there remain regional differences
in access site practice despite the fact that overall UK
practice has changed signiﬁcantly to predominantly
TRA. For examples, centers in Shefﬁeld, Cumbria, and
Lincolnshire are still performing more than 50% of
their cases via the femoral route in patients under-
going PCI following thrombolysis.
ACCESS SITE AND OUTCOMES IN tPCI. Morta l i ty .
Of the 4,959 patients in the TRA group, 89 (1.8%) died
in hospital, 119 (3.7%) died by 30 days. and 181 (5.6%)
died in 1 year, compared with 247 (4.7%), 349 (7.5%),
and 458 (9.8%) patients in the TFA group, respec-
tively. Table 2 presents the adjusted odds of out-
comes by access site. Comparing the TRA group to the
TFA group, 1-year mortality rates were similar (odds
ratio [OR]: 0.82; 95% conﬁdence interval [CI]: 0.66 to
1.02; p ¼ 0.08), but TRA was associated with reduced
in-hospital (OR: 0.59; 95% CI: 0.42 to 0.82; p ¼ 0.002)
and 30-day (OR: 0.72; 95% CI: 0.55 to 0.94; p ¼ 0.01)
mortality risk.
Access s i te compl i cat ions , ma jor b leed ing , and
MACE. The TRA group experienced signiﬁcantly
less access site complications (n ¼ 33, 0.6%), major
bleeding (n ¼ 49, 1%), and MACE (n ¼ 135, 2.7%)
than the TFA group did (access site complications:
n ¼ 136, 2.5%; major bleeding: n ¼ 116, 2.2%; MACE:
n ¼ 302, 5.7%). After adjustment for all patient and
clinical characteristics, TRA was associated with sig-
niﬁcant reduction in access site–related complications
(OR: 0.30; 95% CI: 0.20 to 0.45; p < 0.001), in-hospital
MACE risk (OR: 0.72; 95% CI: 0.56 to 0.94; p ¼ 0.01),
and major bleeding (OR: 0.45; 95% CI: 0.31 to 0.66;
p < 0.001), compared with the TFA group (Table 2).
PROPENSITY SCORE MATCHING. Propensity score
matching to correct for baseline characteristics
showed no difference in results (Table 3, balance
diagnostics for propensity model are presented in
Online Table 1). TRA remained signiﬁcantly associ-
ated with reduced risk of in-hospital mortality, access
site complications, and major bleeding.
DISCUSSION
This is one of the largest analyses demonstrating the
temporal trends, regional practices, and impact of
TRA on clinical outcomes in patients undergoing PCI
following thrombolysis. Approximately 38% of the
patients received tPCI in 2007, which was reduced to
1.3% in 2014 with a concomitant national increase in
use of PPCI for STEMI patients. Although the overall
use of tPCI has reduced over time, there remain
important regional differences within the United
Kingdom. In over a third of the regions, up to 10% of
STEMI patients receiving PCI received thrombolysis
whereas in other areas this was >50% with signiﬁcant
regional differences in access site practice. Our study
shows that compared with TFA, the use of TRA is
associated with reduced in-hospital and longer-term
mortality, in-hospital MACE, in-hospital major
FIGURE 2 Temporal Trends in Thrombolytic PCI Activity and Use of Radial Access in
United Kingdom
(A) Comparison between ST-segment elevation myocardial infarction (STEMI) primary
percutaneous coronary intervention (PPCI) and thrombolytic percutaneous coronary
intervention (PCI) activity in the United Kingdom from 2007 to 2014. (B) Use of radial
access in thrombolytic PCI and PPCI for STEMI in the United Kingdom from 2007
to 2014.
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bleeding, and access site complications in patients
undergoing PCI post-thrombolysis.
Due to development of improved service structures
and better systems of care such as regional STEMI
networks (27,28), use of thrombolysis has signiﬁ-
cantly reduced over the last decade in countries
including the United Kingdom, Denmark, Germany,
and Austria (3). However, thrombolysis followed by
PCI still remains an important reperfusion strategy in
many countries across the world (6,7,29,30). The rates
of PCI after thrombolysis vary between 8% (Europe)
and 25% (the United States) (7,31). In our study, this
proportion is lower, with only 7.3% undergoing PCI
after thrombolysis over the study period. Interest-
ingly, the temporal analysis demonstrates a signiﬁ-
cant reduction in number of patients requiring PCI
after thrombolysis from 38% to 1.3% over the past
decade. Data captured from the Myocardial Ischaemia
National Audit Project in the United Kingdom re-
ported that use of thrombolysis has declined to <1%
in 2015 with the concomitant rise in use of PPCI to
99% (32). The decline in thrombolysis in United
Kingdom over the last few years has resulted in less
need of tPCI. This trend was also mirrored by signif-
icant change in access site practice with an increase in
the use of radial access from 36.3% in 2007 to 83.5%
in 2014.
Data from several randomized trials and observa-
tional studies have consistently demonstrated that
use of TRA is associated with lower risk of major
bleeding, vascular complications, and mortality
(14,23,25,33,34). Adoption of TRA yields even greater
beneﬁts over TFA in patients with high baseline
bleeding risk (33). In the RIFLE-STEACS (Radial
Versus Femoral Investigation in ST Elevation Acute
Coronary Syndrome) trial, TRA was associated with
signiﬁcant reduction in cardiac mortality (5.2% vs.
9.2%; p ¼ 0.020) and bleeding complications (7.8% vs.
12.2%; p ¼ 0.026) (15). In one the largest trials to date
comparing TRA versus TFA, the MATRIX (Minimising
Adverse Haemorrhagic Events by Transradial Access
Site and Systemic Implementation of angioX) trial
reported a 28% reduction in mortality (1.6% vs. 2.2%;
p ¼ 0.045) (14) with a reduction in net adverse clini-
cally events (9.8% vs. 11.7%; p ¼ 0.009) mainly driven
by a marked reduction in Bleeding Academic
Research Consortium 3 or 5 major bleeding in the TRA
group. The appended updated meta-analysis
including MATRIX trial patients also showed that
TRA was associated with reduced major bleeding,
MACE, and all-cause mortality without any hetero-
geneity in the results. Patients undergoing PCI
following recent thrombolysis are among the highest
risk patient groups of sustaining major bleeding
complications and would therefore have the greatest
beneﬁt from undergoing PCI through the transradial
approach. Our data are consistent with this and not
only show that odds of major bleeding are reduced by
55% associated with the use of TRA, but also translate
into a reduced mortality and MACE risk in patients
undergoing PCI after thrombolysis.
There is limited evidence about the impact of TRA
on clinical outcomes in patients requiring PCI
following thrombolysis (18–20). In a previous analysis
of the CathPCI registry, TRA was associated with a
signiﬁcant reduction in major bleeding (OR: 0.67; 95%
CI: 0.52 to 0.87; p ¼ 0.003) but no difference between
in-hospital mortality (20). However, the use of TRA
was <15% in this study compared with our analysis
where use of TRA was >50%. Furthermore, our
analysis is over a timeframe in which TRA has become
the default access site choice in patients undergoing
PCI in the United Kingdom, with rates >80% in 2015
(13), whereas in the U.S. uptake is around 10% (35).
Another important difference was the fact that criti-
cally ill patients such as those with hemodynamic
compromise requiring intra-aortic balloon pump or
mechanical support and patients needing in-hospital
coronary artery bypass grafting were also included
in the current analysis. Finally, this is the ﬁrst study
TABLE 2 Adjusted Outcomes Following Transradial Access and
Transfemoral Access
Adverse Outcome
Sample
Size Odds Ratio (95% CI) p Value
In-hospital death 10,209 0.59 (0.42 to 0.83) 0.002
Access site complications 10,209 0.30 (0.20 to 0.45) <0.001
Major bleeding 10,209 0.45 (0.31 to 0.66) <0.001
MACE 10,209 0.72 (0.56 to 0.94) 0.01
30-day mortality 7,841 0.72 (0.55 to 0.94) 0.01
1-yr mortality 7,841 0.82 (0.66 to 1.02) 0.08
CI ¼ conﬁdence interval; other abbreviations as in Table 1.
TABLE 3 Propensity Score Matching Analysis on 10 Imputed Datasets, Reporting
Average Treatment Effects
Radial vs. Femoral n Coefﬁcient 95% CI p Value
In hospital death 8,769 0.01078 0.02132 to 0.00025 0.04
Access site complications 8,769 0.01921 0.02675 to 0.01167 <0.001
Major bleeding 8,796 0.01138 0.01859 to 0.00416 <0.002
MACE 8,769 0.01045 0.02205 to 0.00113 0.07
30-day mortality 7,167 0.01158 0.02578 to 0.00262 0.11
1-yr mortality 7,167 0.01039 0.02734 to 0.00655 0.22
Abbreviations as in Tables 1 and 2.
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to report impact of TRA on longer-term mortality in
patients undergoing PCI in the thrombolysis setting.
Our study has several strengths: it is one of the
largest to date describing national patterns of access
site practice in patients requiring PCI following
thrombolysis. The BCIS dataset records information
about almost every single PCI procedure undertaken
in United Kingdom providing real-world insight into
management of patients requiring PCI following
thrombolysis. We were able to include high-risk
patients such as those requiring inotropic support
and hemodynamic instability, who are often
excluded from randomized trials. Finally, this is
ﬁrst study to illustrate the impact of access site
practice on longer-term mortality in this cohort of
patients.
STUDY LIMITATIONS. We acknowledge that
although the mortality outcomes in the BCIS are
robustly linked with the Ofﬁce of National Statistics,
all other complications of PCI are reliant on oper-
ator recording and may be under-reported. Our
analysis focuses on outcomes associated with the
access site used rather than an intention to treat
(i.e., that access site that was ﬁrst attempted). The
BCIS dataset does not contain information on access
site crossover resulting from failure for cases in
which multiple access sites were used, although
such cases are were 5.2% of the total number of
procedures in the current analysis and were
excluded from the analysis when the access site
used was not clear. Many of the cases with multiple
access sites are likely to represent cases in which
radial was attempted and then the case was con-
verted to femoral. In addition, these cases are likely
to be more complicated, and if classiﬁed as femoral,
the analyses would tend to overestimate the rela-
tive beneﬁt of radial access (13,17). Finally, our
analysis is observational in nature and prone to
unmeasured confounders. Therefore, a causal rela-
tionship cannot be inferred between access site
practice and clinical outcomes.
CONCLUSIONS
In one of the largest analysis of patients receiving PCI
after thrombolysis, use of TRA was associated with
reduced risk of major bleeding, access site complica-
tions, in-hospital mortality, and MACE. Our analysis
suggests that where PCI is required after thrombol-
ysis, use of the radial access site may translate to
more favorable clinical outcomes.
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